AGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Agenus Inc (AGEN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows potential in its cancer treatment advancements and has seen revenue growth, the financial performance is weak with significant losses, and there are no strong technical or trading signals indicating an immediate buying opportunity. Additionally, the stock's recent price trend and lack of significant positive catalysts suggest a cautious approach.
The MACD is slightly positive but contracting, RSI is neutral at 43.702, and moving averages are converging, indicating no clear trend. Key support is at 3.086, and resistance is at 3.988. The stock is trading below its pivot level of 3.537, suggesting bearish sentiment.
The company is advancing its BOT+BAL program for treatment-resistant cancers, with updates on global access programs and strategic priorities. Revenue increased by 27.45% YoY in Q4 2025.
The stock experienced a regular market decline of -3.37%, and there are no significant hedge fund or insider trading trends. No recent congress trading data is available.
In Q4 2025, revenue increased to $34.2M (+27.45% YoY), but net income dropped to -$10.63M (-76.84% YoY), and EPS fell to -0.31 (-84.50% YoY). Gross margin improved slightly to 100% (+0.44% YoY).
No recent analyst rating or price target changes are available for AGEN.
